期刊文献+

炎症相关因子基因多态性与弥漫大B细胞淋巴瘤的易感性研究 被引量:2

Gene Polymorphism of Inflammation-related Cytokines Correlates with the Susceptibility to DLBCL
下载PDF
导出
摘要 目的:探讨甘肃汉族人群中炎症相关因子基因多态性与弥漫大B淋巴瘤(diffuse large B-cell lymphoma,DLBCL)发病率的相关性。方法:运用高分辨率溶解曲线(high-resolution melting,HRM)方法检测炎症因子基因多态性。结果:IL-1RA的rs4251961位点CC纯合子基因型携带者与患DLBCL风险有关(以TT为参照,CC基因型的OR为0.83,95%CI=0.697-0.997,P<0.05),但与T等位基因相比,C等位基因与DLBCL风险升高显著相关(OR=8.83,95%CI=1.909-40.813,P<0.01)。结论:IL-1RA的rs4251961位点的次等位基因C与DLBCL的易患性显著相关。 Objective: To investigate the relationship of gene polymorphisms of inflammattion related cytokines with incidence of diffuse large B-cell lymphoma(DLBCL) in Gansu Han population. Methods: The gene polymorphism of inflammation-related cytokines were detected by high-resolution melting (HRM) curve. Results: The homozygous CC genotype carrying IL-1RA rs4251961 gene locus was related with the risk of DLBCL in comparison with homozygous TT, the OR was 0. 83 of homozygous CC, 95 % CI = 0. 697 - 0. 997, P 〈 0. 05 ), while the C allele of IL-1RA rs4251961 gene locus significantly correlated with the high incidence of diffuse large B-cell lymphoma compared with T allele( OR =8.83, 95% CI = 1.909 -40. 813,P 〈 0.01 ). Conclusion: The minor allele C of IL-1RA rs4251961 gene locus significantly relates with the susceptibility to DLBCL.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2017年第2期444-448,共5页 Journal of Experimental Hematology
基金 甘肃省科技支撑计划资助项目(1104FKCA134) 甘肃省中医药管理局课题(GZK-2012-24) 甘肃省肿瘤医院 甘肃省医学科学研究院中青年科技人才创新工程项目(YKZ-2013-4)
关键词 DLBCL HRM 基因多态性 炎症因子 diffuse large B-cell lymphoma high-resolution melting curve genetic polymorphism inflammation- related cytokine
  • 相关文献

参考文献5

二级参考文献67

  • 1周立强,孙燕,谭文勇,李陶,王琦路,冯凤仪,王金万,储大同,石远凯,李晔雄,孙云田,吕宁.非霍奇金淋巴瘤1125例临床病理分析[J].癌症进展,2006,4(5):391-397. 被引量:47
  • 2王军,张新华,周敏,冉启杰,杜光祖.弥漫大B细胞淋巴瘤96例临床及预后分析[J].现代肿瘤医学,2007,15(11):1658-1659. 被引量:7
  • 3Sterdlow SH,Campo E,Harris NL,et al. WHO Classification ofTumors of Haematopoietic and Lymphoid Tissues. Vol 2:IARCWHO Classification of Tumors,No 2. Lyon:IARC Press,2008.
  • 4Hans CP,Weisenburge DD,Greiner TC,et al. Confirmation ofthe molecular classification of diffuse large B-cell lymphoma byimmunohistochemistry using a tissue microarray. Blood,2004;103(1):275 -282.
  • 5Matolcsy A,Chadbum A,Knowles D. de novo CD5-positive andRichter's syndrome-associated diffuse large B cell lymphomas aregenotypically distinct. Am J Pathol,1995 ;147( 1) :207 -216.
  • 6Yamaguchi M,Seto M,Okamoto M,et al. de novo CD5 + diffuselarge B-cell lymphoma:clinicopathologic study of 109 patients.Blood,2002;99(3) :815-821.
  • 7Yamaguchi M,Nakamura N,Suzuki R,et al. de novo CD5 +diffuse large B-cell lymphoma :results of a detailed clinicopatho-logical review in 120 patients. Haematologica,2008 ; 93 (8) :1195-1202.
  • 8Yamaguchi M,Ohno T,Oka K,et al. de novo CD5-positivediffuse large B-cell lymphoma :clinical characteristics andtherapeutic outcome. Br J Haematol,1999; 105(4) :1133 - 1139.
  • 9Niitsu N,Okamoto M,Tamaru JI,et al. Clinicopathologiccharacteristics and treatment outcome of the addition of rituximab tochemotherapy for CD5-positive in comparison with CD5-negativediffuse large B-cell lymphoma. Ann Oncol,2010; 21 (10) :2069 -2074.
  • 10Miyazakil K,Yamaguchi M,Suzuki R,et al. CD5-positivediffuse large B-cell lymphoma :a retrospective study in 337 patientstreated by chemotherapy with or without rituximab. Ann Oncol,2011; 22(7) :1601 -1607.

共引文献41

同被引文献7

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部